Zusammenfassung
Biologische Substanzen, wie Interferone (IFN), IL-2 und Tumornekrosefaktor (TNF-alpha), kommen in der Behandlung von Patienten mit metastasiertem Nierenzellkarzinom gegenwärtig nur innerhalb von prospektiven Studien in Frage, da für keine dieser Stoffe allgemein akzeptierte Therapieprotokolle existieren. In Deutschland ist zudem zu beachten, daß bisher nur das Interleukin-2 vom Bundesgesundheitsamt in Berlin zur Behandlung des Nierenzellkarzinoms zugelassen ist. Von den verschiedenen IFN erscheint IFN-alpha beim Nierenzellkarzinom die geeignetste Substanz zu sein. Bei Gabe von IFN-alpha sind jedoch nur in etwa 15% der Fälle objektive Remissionen zu erwarten wobei die Rate an kompletten Remissionen nur etwa 2% beträgt. Eine Monotherapie mit Interleukin-2 bringt keine signifikant besseren Behandlungsergebnisse als mit Interferon-alpha (IFN-alpha), geht jedoch mit höheren Nebenwirkungen einher. Bei der Kombination von IL-2 mit IFN-alpha lassen sich höhere Remissionsraten als bei der Monotherapie erzielen, wobei jedoch auch hier komplette Remissionen mit etwa 6% sehr selten sind. Der Tumornekrosefaktor befindet sich beim Nierenzellkarzinom noch in einem frühen Stadium der Erprobung.
Summary
At present, biological substances such as interferones (IFN), IL-2 and tumor necrosis factor (TNF-alpha) should be used in the treatment of patients with metastasized renal cell carcinoma only in the course of prospective trials, as there are no generally accepted therapy protocols for any of these substances. In Germany, moreover, it is important to note that only Interleukin-2 has as yet been approved for the treatment of renal cell carcinoma by the Federal Department of Health in Berlin. Of the various interferones. IFN-alpha appears to be the most suitable substance for treatment of metastasized renal cell carcinoma. Nevertheless, after the administration of IFN-alpha, objective remission can be expected in only 15% of all cases, complete remission accounting for only 2% of the total. The results of monotherapy with Interleukin-2 are not significantly better than those with Interferon-alpha, although the former is accompanied by a higher incidence of side-effects. A combination of IL-2 with Interferon-alpha results in higher remission rates than in the case of monotherapy with either substance, although here too, complete remissions, which account for a more 6% of the total, are very rare. The tumor necrosis factor is still at an early stage of testing for renal cell carcinoma.
Literatur
Atzpodien J, Kirchner H: Cancer, cytokines, and cytotoxic cells: Interleukin-2 in the immunotherapy of human neoplasms. Klin Wschr 1990;68:1–11.
Aulitzky W, Gastl G, Aulitzky WE, Herold M, Kemmler J, Mull B, Frick J, Huber C: Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferongamma. J Clin Oncol 1989;7:1875–1884.
Bono AV: Steroid hormones and hormonal treatment in renal cell carcinoma, in De Kernion, Pavone-Macaluso (eds): Tumors of the kidney, Vol 13. Baltimore, Williams & Wilkins, 1986, pp 205–227.
Debruyne FMJ: Interferons and tumor necrosis factor (BRMS) in the management of renal cell carcinoma, in: Immunobiology of renal cell carcinoma. Cleveland, 1989.
De Kernion JB, Sarna JB, Figlin R, Lindner A, Smith RB: The treatment of renal cell carcinoma with human leukocyte alpha-interferon. J. Urol 1983;130:1063–1066.
Eisenhauer E, Wierzbicki R, Venner P, Skillings J, Letendre F: Phase II trial of recombinant tumor necrosis factor (rTNF) in patients with renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 1990;9:139.
Figlin R, De Kernion J, Sarna G, Moldawer N, Saks S: Phase II study of recombinant tumor necrosis factor (rTNF) in patients with metastatic renal cell cancer (RCCa) and malignant melanoma (MM). Proc Am Soc Clin Oncol 1988;7:169.
Fujita T, Asano H, Haide Y, Ono Y, Onshima S, Suzuki K, Aso Y, Ariyoshi Y, Fukushima M, Ota K: Antitumor effects of human lymphoblastoid interferom on advanced renal cell carcinoma. J Urol 1988;139: 256–258.
Goldstein D, Laszlo J: Interferon therapy in cancer: from imaginon to interferon. Cancer Res 1986;46: 4315–4329.
Grups JW, Frohmüller HG: Cyclic interferon gamma treatment of patients with metastatic renal cell carcinoma. Br J Urol 1989;64:218–220.
Heicappell R, Ackermann R: Rationale for immunotherapy of renal cell carcinoma. Urol Res 1990;18:357–372.
Horoszewicz JS, Murphy GP: An assessment of the current use of human interferons in therapy of urological cancers. J Urol 1989;142:1173–1180.
Huber C, Aulitzky W, Gastl G, Aulitzky WE, Herold M, Frick J: Treatment of metastasizing renal cell carcinoma with an optimum biological response modifying dose of r-IFN-gamma. J Biol Resp Modif 1989;98:335.
Kirkwood JM, Ernstoff MS: Interferons in the treatment of human cancer. J Clin Oncol 1984;2:336–352.
Kriegmair M, Hofstetter A: Interferontherapie in der Urologie. Urologe. A 1989;28:116–121.
Krown SE: Therapeutic options in renal cell carcinoma. Sem Oncol 1985;12 (Suppl 5): 13–17.
Krown SE: Interferon treatment of renal cell carcinoma: current status and future prospects. Cancer 1987;59:647–651.
Levens W, Sohn M, Richter R, Räth U, Kempini J, Jakse G: TNF/Gamma interferon in metastatic renal cell carcinoma. Eur Urol 1990;18 (Suppl 1): 148 (abstr).
Morgan DA, Ruscetti FW, Gallo RC: Selective in vitro growth of T-lymphocytes from normal bone marrows. Science 1976;193:1007–1008.
Muss HB: The role of biological response modifiers in metastatic renal cell carcinoma. Sem Oncol 19xx;15 (Suppl 15): 30–34.
Neidhart J, Gagen M, Kisner R, Tuttel R, Whisman J: Therapy of renal cancer with low (LD) and high (HD) dose regimens of human lymphoblastoid interferon (HBLJ: Wellferon). Proc Am Soc Clin Oncol 1984;3:60.
Neidhart JA, Gagen MM, Young D, Tuttle R, Melink TJ, Ziccarrelli A, Kisner D: Interferon-alpha therapy of renal cancer. Cancer Res 1984;44:4140–4143.
Otto U, Schneider A, Denkhaus H, Conrad S: Die Behandlung des metastasierten Nierenkarzinoms mit rekombinantem Alpha-2 oder Gamma-Interferon. Ergebnisse zweier klinischer Phase-II-bzw.-III-Studien. Onkologie 1988;11:185–191.
Otto, U., Schneider AW, Conrad S, Klosterhalfen H: Combined therapy with tumor-necrosis-factor-alpha and alpha-2a-interferon: a promising new approach to metastatic renal cell carcinoma. J Urol 1990;143:392A.
Quesada JR, Swanson DA, Trindade A, Gutterman JU: Renal cell carcinoma: antitumor effects of leukocyte interferon. Cancer Res 1983;43:940–947.
Quesada JR, Swanson DA, Gutterman JU: Phase II study of interferon alpha in metastatic renal cell carcinoma. J Clin Oncol 1985;3:1086–1092.
Ratliff TL, Shapiro A, Catalona WJ, in Ratliff TL, Catalona W (eds): Urologic Oncology. Boston, Nijhoff, 1984, pp 211–238.
Rosenberg SA: The development of new immunotherapies for the treatment of cancer using interleukin-2. A review. Ann Surg 1988;208:121–135.
Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889–897.
Wirth M: The current use of interferons, interleukin-2 and tumor necrosis factor in renal cell cancer. Urol Int 1991;47:219–230.
Wirth M: Stellenwert der Interferone, des Interleukin-2 und des Tumornekrosefaktors in der Therapie des Nierenzellkarzinoms. Urologe A 1991;30:77–80.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wirth, M. Immuntherapie beim Nierenzellkarzinom. Acta Chir Austriaca 25, 32–34 (1993). https://doi.org/10.1007/BF02602027
Issue Date:
DOI: https://doi.org/10.1007/BF02602027